The new system, described in Frontiers in Signal Processing, achieves a classification accuracy of 99.83 percent on a balanced dataset of 14,390 chest CT images, correctly distinguishing fibrotic lungs from healthy ones with a sensitivity of 99.93 percent and a specificity of 99.72 percent. But the numbers alone tell only half the story. What sets this architecture apart is its explainability: using a visualization technique called Grad-CAM++, the model generates heatmaps that highlight exactly which regions of the lung drove its decision, giving radiologists a window into the machine’s reasoning rather than forcing them to trust an opaque verdict.

The engineering challenge the team faced was fundamental to how fibrosis manifests. Unlike tumors or fractures, pulmonary fibrosis announces itself through slight, diffuse, and seemingly random texture changes scattered across the lung parenchyma. Conventional convolutional neural networks like ResNet50V2, the backbone of the new system, rely on fixed receptive fields and hierarchical feature extraction — a design that struggles to capture both the fine-grained fibrotic textures and the long-range contextual patterns the disease produces. Worse, without explicit spatial attention, such models can be distracted by irrelevant structures like ribs and background noise, contributing to the false positives that have plagued earlier automated approaches.

The researchers’ solution is a module they call Pyramid Spatial Atrous Channel Attention, or PSACA, grafted onto the ResNet50V2 transfer learning framework. The design reorders the logic of attention itself: spatial attention is applied first, directing the network’s focus to disease-relevant lung regions before anything else happens. Then comes Atrous Spatial Pyramid Pooling, a clever technique built on parallel dilated convolutions with dilation rates of 1, 5, 10, and 15. Lower rates capture intricate structural details such as edges and vascular patterns, while higher rates encode broader contextual information about patch-level and global lung architecture. Finally, channel attention selectively amplifies the most informative feature channels, completing a three-stage refinement pipeline that transforms raw CT data into a rich, fibrosis-aware representation.

Placement matters as much as design. The PSACA block was embedded at Stage 3 and Stage 4 of ResNet50V2 — the levels where the network learns mid-level structural features like localized fibrosis textures and high-level semantic patterns of lung abnormalities. Earlier stages, which capture only edges and simple textures, were left untouched, keeping computational complexity low while maximizing discriminative power where it counts. An ablation study confirmed the wisdom of this strategy: the baseline ResNet50V2 achieved 98.61 percent accuracy, but adding PSACA at Stage 3 or Stage 4 individually pushed performance to 99.69 percent, and combining both stages yielded the full 99.83 percent. The components, the authors found, contribute complementary rather than redundant information.

The team began by benchmarking eight pre-trained deep learning architectures — VGG19, MobileNetV2, ResNet-50, ResNet50V2, ResNet-152V2, DenseNet-121, DenseNet-169, and DenseNet-201 — all initialized with ImageNet weights and fine-tuned on the fibrosis dataset. ResNet50V2 emerged as the strongest performer, and the researchers then customized it further, unfreezing the final 20 layers, adding a global average pooling layer, a dense layer of 512 neurons with ReLU activation, and a 50 percent dropout layer to guard against overfitting before a final sigmoid output for binary classification. Training used the Adam optimizer with a learning rate of 0.001, binary cross-entropy loss, a batch size of 32, and 30 epochs — hyperparameters identified through Bayesian optimization, which the authors found converged faster than grid or random search.

The dataset itself, sourced from Kaggle, was carefully balanced: 7,195 normal CT images and 7,195 fibrosis images, split 60/20/20 into training, validation, and test sets. On the held-out test data, the model missed just one fibrotic scan out of 1,439 and misclassified only four normal scans. The receiver operating characteristic curve told an even more striking story, with an area under the curve of 1.00 — a perfect equilibrium between sensitivity and specificity that, if it holds up under independent scrutiny, would represent a remarkable discriminatory ability for any diagnostic tool.

The explainability layer may prove to be the system’s most clinically valuable feature. Grad-CAM++ heatmaps, superimposed on lung-only CT images after segmentation, consistently lit up fibrosis-affected tissue along lung borders, with green marking affected regions and red flagging highly confident lesion cores. This weakly supervised localization allows radiologists to verify that the model is attending to genuine pathological features rather than artifacts — a critical safeguard for clinical trust. The authors note that such visual validation enhances radiologist confidence and addresses the transparency deficits that have hindered AI adoption in interstitial lung disease imaging, a concern echoed across recent reviews of machine learning in radiology.

Compared with prior approaches — from a multiscale rotation-invariant CNN that reached 90 percent accuracy to a CNN-transformer parallel fusion model at 97.6 percent — the PSACA-ResNet50V2 system represents a substantial leap. Yet the authors are candid about its limits. The model was trained and evaluated on a single publicly available dataset, and real-world clinical data varies widely in acquisition protocols, scanner types, and patient demographics. Validation on multi-institutional datasets is the necessary next step before the system can move toward real-time diagnostic deployment, and the researchers suggest extending the framework to multi-class classification of multiple lung diseases.

Still, the study offers a compelling glimpse of where medical AI is heading: not toward ever-larger black boxes, but toward architectures engineered from the ground up to see the way clinicians see — attending to subtle textures, weighing context across scales, and explaining themselves in images a radiologist can read. For a disease where median survival is measured in years and diagnosis is measured in missed opportunities, an algorithm that can both detect fibrosis with 99.83 percent accuracy and show exactly where it looked may be exactly the kind of transparent ally pulmonary medicine has been waiting for.

Subject of Research: Explainable deep learning model for pulmonary fibrosis diagnosis from chest CT images

Article Title: Multi-scale pyramid spatial atrous channel attention enhanced ResNet50V2 for explainable pulmonary fibrosis diagnosis

Article References: Mahapackialakshmi, K., & Jaffino, G. (2026). Multi-scale pyramid spatial atrous channel attention enhanced ResNet50V2 for explainable pulmonary fibrosis diagnosis. Frontiers in Signal Processing, 6, Article 1787092. https://doi.org/10.3389/frsip.2026.1787092

Image Credits: AI Generated

DOI: 10.3389/frsip.2026.1787092

Keywords: pulmonary fibrosis, deep learning, medical imaging, explainable AI, Grad-CAM++, ResNet50V2, attention mechanisms, chest CT, artificial intelligence, diagnostic AI, Multi-scale, pyramid